timoptic-xe solution (à libération prolongée)
elvium life sciences - timolol (maléate de timolol) - solution (à libération prolongée) - 0.5% - timolol (maléate de timolol) 0.5% - beta-adrenergic agents
dorzolamide-timolol pf solution
micro labs limited - timolol (maléate de timolol); dorzolamide (chlorhydrate de dorzolamide) - solution - 5mg; 20mg - timolol (maléate de timolol) 5mg; dorzolamide (chlorhydrate de dorzolamide) 20mg
timoptic solution
elvium life sciences - timolol (maléate de timolol) - solution - 0.5% - timolol (maléate de timolol) 0.5% - beta-adrenergic agents
timoptic-xe solution (à libération prolongée)
purdue pharma - timolol (maléate de timolol) - solution (à libération prolongée) - 0.25% - timolol (maléate de timolol) 0.25% - beta-adrenergic agents
travoprost/timolol eg 40 µg/ml - 5 mg/ml collyre sol. flac. compte-gouttes
eg sa-nv - maléate de timolol 6,83 mg/ml - eq. timolol 5 mg/ml; travoprost 0,04 mg/ml - collyre en solution - 40 µg/ml - 5 mg/ml - travoprost 0.04 mg/ml; maléate de timolol 6.83 mg/ml - timolol, combinations
fingolimod ab 0.5 mg gél.
aurobindo sa-nv - chlorhydrate de fingolimod 0,56 mg - eq. fingolimod 0,5 mg - gélule - fingolimod
fingolimod reddy 0.5 mg gél.
reddy holding gmbh - chlorhydrate de fingolimod 0,56 mg - eq. fingolimod 0,5 mg - gélule - fingolimod
latanoprost-timolol ab 50 µg/ml - 5 mg/ml collyre sol. flac. compte-gouttes
aurobindo sa-nv - maléate de timolol 6,83 mg/ml - eq. timolol 5 mg/ml; latanoprost 0,05 mg/ml - collyre en solution - 0,005 % - 0,5 % - maléate de timolol 6.83 mg/ml; latanoprost 0.05 mg/ml - timolol, combinations
fingolimod mylan
mylan ireland limited - le chlorhydrate de fingolimod - la sclérose en plaques, sep récurrente-rémittente - immunosuppresseurs - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 et 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
fingolimod krka 0.5 mg gél.
krka d.d. novo mesto d.d. - chlorhydrate de fingolimod 0,56 mg - eq. fingolimod 0,5 mg - gélule - fingolimod